Salemonline Journal

Brain Metastasis from Breast Cancer Pipeline Report 2023: Emerging Therapies and Key pharma players involved by DelveInsight | Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criteriu

 Breaking News
  • No posts were found

Brain Metastasis from Breast Cancer Pipeline Report 2023: Emerging Therapies and Key pharma players involved by DelveInsight | Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criteriu

February 28
20:28 2023
Brain Metastasis from Breast Cancer Pipeline Report 2023: Emerging Therapies and Key pharma players involved by DelveInsight | Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criteriu
Brain Metastasis from Breast Cancer Pipeline

Central nervous system or brain metastases traditionally occur in 10-16% of metastatic breast cancer patients and are associated with a dismal prognosis. The development of brain metastases has been associated with young age, and tumors that are estrogen receptor negative, Her-2+ or of the basal phenotype. Diagnosis can be done through MRI (magnetic resonance imaging) study of the brain.In rare cases, biopsies are performed to confirm the diagnosis.

 

Brain Metastasis from Breast Cancer Pipeline Insight, 2023 report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Metastasis from Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Request for sample report here: https://www.delveinsight.com/sample/brain-metastasis-from-breast-cancer-pipeline-insight

 

Brain Metastasis from Breast Cancer Phases

DelveInsight’s Brain Metastasis from Breast Cancer pipeline report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Brain Metastasis from Breast Cancer Drugs Pipeline:

ANG1005: Angiochem

ANG-1005 is a peptide-drug conjugate containing paclitaxel covalently linked to a peptide (Angiopep-2). The drug gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the Blood brain barrier. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. A Phase III clinical trial is evaluating ANG-1005 to treat brain metastasis associated with breast cancer.

Pembrolizumab: Merck Sharp & Dohme

Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. KEYTRUDA binds to the PD⁠-⁠1 receptor, blocking both immune-suppressing ligands, PD‑L1 and PD‑L2, from interacting with PD⁠-⁠1 to help restore T-cell response and immune response. The drug is currently being evaluated in Phase I/II stage of development for the treatment of patients with Brain Metastases In Breast Cancer Patients.

 

Request for sample report here: https://www.delveinsight.com/sample/brain-metastasis-from-breast-cancer-pipeline-insight

 

Key Brain Metastasis from Breast Cancer companies:

Some of the companies working in the market are Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma and others.

 

Current Brain Metastasis from Breast Cancer Treatment Scenario and Brain Metastasis from Breast Cancer Emerging Therapies:

  • How many companies are developing Brain Metastasis from Breast Cancer drugs?
  • How many Brain Metastasis from Breast Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brain Metastasis from Breast Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Brain Metastasis from Breast Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Brain Metastasis from Breast Cancer and their status?
  • What are the key designations that have been granted to the emerging Brain Metastasis from Breast Cancer drugs?

 

Request for sample report here: https://www.delveinsight.com/sample/brain-metastasis-from-breast-cancer-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Brain Metastasis from Breast Cancer: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

ANG1005: Angiochem

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early stage products (Phase I)

  • Comparative Analysis

Pembrolizumab: Merck Sharp & Dohme

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Brain Metastasis from Breast Cancer Key Companies

Brain Metastasis from Breast Cancer Key Products

Brain Metastasis from Breast Cancer- Unmet Needs

Brain Metastasis from Breast Cancer- Market Drivers and Barriers

Brain Metastasis from Breast Cancer- Future Perspectives and Conclusion

Brain Metastasis from Breast Cancer Analyst Views

Brain Metastasis from Breast Cancer Key Companies

Appendix

 

Related Reports:

Age Related Vision Dysfunction Market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Related Articles